Ribociclib & Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

Conditions:   Metastatic Breast Cancer;   Recurrent Ovarian Carcinoma Interventions:   Drug: Ribociclib;   Drug: Belinostat Sponsors:   University of Utah;   Novartis;   Acrotech Biopharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials